$558 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 64 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KDMN | New | KADMON HLDGS INC | $11,167,000 | – | 3,333,333 | +100.0% | 2.00% | – |
| IMMU | New | IMMUNOMEDICS INCcall | $9,332,000 | – | 667,500 | +100.0% | 1.67% | – |
| DBVT | New | DBV TECHNOLOGIES S Aput | $8,488,000 | – | 200,000 | +100.0% | 1.52% | – |
| CLVS | New | CLOVIS ONCOLOGY INCcall | $6,592,000 | – | 80,000 | +100.0% | 1.18% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,524,000 | – | 300,000 | +100.0% | 0.81% | – |
| FXI | New | ISHARES TRput | $4,404,000 | – | 100,000 | +100.0% | 0.79% | – |
| SGEN | New | SEATTLE GENETICS INCput | $3,809,000 | – | 70,000 | +100.0% | 0.68% | – |
| TOCA | New | TOCAGEN INC | $3,129,000 | – | 251,112 | +100.0% | 0.56% | – |
| FENC | New | FENNEC PHARMACEUTICALS INC | $2,773,000 | – | 250,000 | +100.0% | 0.50% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $2,637,000 | – | 70,000 | +100.0% | 0.47% | – |
| FOLD | New | AMICUS THERAPEUTICS INCcall | $2,277,000 | – | 151,000 | +100.0% | 0.41% | – |
| SGEN | New | SEATTLE GENETICS INCcall | $2,176,000 | – | 40,000 | +100.0% | 0.39% | – |
| RMTI | New | ROCKWELL MED INCput | $2,140,000 | – | 250,000 | +100.0% | 0.38% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $2,104,000 | – | 15,000 | +100.0% | 0.38% | – |
| CNC | New | CENTENE CORP DELput | $1,935,000 | – | 20,000 | +100.0% | 0.35% | – |
| NITE | New | NIGHTSTAR THERAPEUTICS PLCadr | $1,920,000 | – | 100,000 | +100.0% | 0.34% | – |
| EVH | New | EVOLENT HEALTH INCcall | $1,477,000 | – | 83,000 | +100.0% | 0.26% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $1,451,000 | – | 58,525 | +100.0% | 0.26% | – |
| CBMXW | New | COMBIMATRIX CORPORATION*w exp 03/18/202 | $1,411,000 | – | 564,200 | +100.0% | 0.25% | – |
| AXDX | New | ACCELERATE DIAGNOSTICS INCput | $1,347,000 | – | 60,000 | +100.0% | 0.24% | – |
| EVTC | New | EVERTEC INCput | $1,090,000 | – | 68,800 | +100.0% | 0.20% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INCput | $1,081,000 | – | 20,000 | +100.0% | 0.19% | – |
| TDOC | New | TELADOC INCput | $995,000 | – | 30,000 | +100.0% | 0.18% | – |
| AMAG | New | AMAG PHARMACEUTICALS INCput | $923,000 | – | 50,000 | +100.0% | 0.16% | – |
| CBMX | New | COMBIMATRIX CORPORATION | $839,000 | – | 111,912 | +100.0% | 0.15% | – |
| MDXG | New | MIMEDX GROUP INCput | $832,000 | – | 70,000 | +100.0% | 0.15% | – |
| LXRX | New | LEXICON PHARMACEUTICALS INCput | $492,000 | – | 40,000 | +100.0% | 0.09% | – |
| DBVT | New | DBV TECHNOLOGIES S Acall | $382,000 | – | 9,000 | +100.0% | 0.07% | – |
| AXGT | New | AXOVANT SCIENCES LTDcall | $140,000 | – | 20,300 | +100.0% | 0.02% | – |
| OTIC | New | OTONOMY INCcall | $57,000 | – | 17,500 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.